Atossa Genetics (ATOS) Posts Narrower Q2 Loss

August 12, 2016 8:13 AM EDT
Get Alerts ATOS Hot Sheet
Trade ATOS Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Atossa Genetics (NASDAQ: ATOS) reported Q2 EPS of ($0.05), versus ($0.11) reported last year.

For the three months and six months ended June 30, 2016, the Company recorded a net loss of $1.7 million and $4.0 million, respectively.

Atossa's important recent developments include the following:

  • In August, 2016, Atossa Genetics Settled Litigation With Besins Healthcare, to receive Cash Payment of $1.76 Million, License Agreement Terminated
  • In June 2016, Atossa Genetics Initiated an Additional Drug Development Program with Oral Endoxifen for Patients Refractory to Tamoxifen
  • In May 2016, Atossa Genetics Announced a $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC
  • In March 2016, Atossa Genetics Opened its Phase 2 Clinical Trial of Intraductal Fulvestrant Administration in Women with DCIS or Breast Cancer

For earnings history and earnings-related data on Atossa Genetics (ATOS) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment